Statin use among older Finns stratified according to cardiovascular risk

European Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2013, Pages 261-267

  Upmeier, Eveliina ^a,b,c   Korhonen, Maarit Jaana ^a   Helin Salmivaara, Arja ^a,d   Huupponen, Risto ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TURKU CITY HOSPITAL   (Finland)

^d HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

Author keywords

Cardiovascular risk; Elderly; Incidence; Prevalence; Statins

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY LIVING; DISEASE REGISTRY; DRUG USE; ELDERLY CARE; FEMALE; FINLAND; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SEX DIFFERENCE; STANDARDIZATION; TREND STUDY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 84873721570     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1328-0     Document Type: Article

References (36)

1. Walley T, Folino-Gallo P, Stphens P, Van Ganse E (2005) Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 60:543-551 (Pubitemid 41532455)
2. Robinson J, Booth B (2010) Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 4:483-490
3. Grundy S, Cleeman J, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110:227-239 (Pubitemid 38924592)
4. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32:1769-1818
5. Redberg RF, Katz M, Grady D (2011) To make the case - Evidence is required. Arch Intern Med 171:1594
6. Ridker PM, Danielson E, Fonseca FA, for the JUPITER Study Group et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
7. Brugts JJ, Yetgin T, Hoeks SE et al (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338:b2376
8. Ray KK, Seshasai S, Erqou S et al (2010) Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170:1024-1031
9. Taylor F, Ward K, Moore TH, et al (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD00481642
10. Miettinen TA, Pyörälä K, Olsson AG, for the Scandinavian Simvastatin Study Group et al (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Study (4S). Circulation 96:4211-4218 (Pubitemid 28007446)
11. Lewis SJ, Moye LA, Sacks FM et al (1998) Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med 129:681-689 (Pubitemid 28507140)
12. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22 (Pubitemid 34756487)
13. Shephard J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630 (Pubitemid 35379733)
14. Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278 (Pubitemid 41416582)
15. Hunt D, Young P, Simes J, for the LIPID investigators et al (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 134:931-940 (Pubitemid 32466232)
16. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ (2008) Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51:37-45
17. Ali R, Alexander KP (2007) Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. Am J Geriatr Pharmacother 5:52-63 (Pubitemid 47099505)
18. Robinson J, Bakris G, Torner J, Stone NJ, Wallace R (2007) Is it time for a cardiovascular primary prevention trial in the elderly? Stroke 38:441-450 (Pubitemid 46184321)
19. Petersen LK, Christensen K, Kragstrup J (2010) Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80 + -year olds. Age Ageing 39:674-680
20. Huisman-Baron M, van der Veen L, Jansen PA, van Roon EN, Brouwers JR, van Marum RJ (2011) Criteria for drug selection in frail elderly persons. Drugs Aging 28:391-402
21. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen PJ, Huupponen R (2008) Shift of statin use towards the elderly in 1995-2005: a nationwide register study in Finland. Br J Clin Pharmacol 66:405-410
22. Hjemdahl P, Allhammar A, Heaton C (2009) SBU should investigate what is an evidence-based and cost-effective use of statins. Lakartidningen 106:1992-1994
23. Kildemoes HW, Andersen M, Stovring H (2010) The impact of aging and changing utilization patterns on future cardiovascular drug expenditure: a pharmacoepidemiological projection approach. Pharmacoepidemiol Drug Saf 19:1276-1286
24. Geleedst-De Vooght M, Maitland-van der Zee A-H, Schalekamp T, Mantel-Teeuwisse A, Jansen P (2010) Statin prescribing in the elderly in the Netherlands. A pharmacy database time trend study. Drugs Aging 27:589-596
25. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC (2007) Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. Am J Cardiol 100:1061-1067 (Pubitemid 47404456)
26. Candrilli SD, Kuznik A, Mendys PM, Wilson DJ (2010) Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged >65 years by lipid-lowering medication use status. Postgrad Med 122:142-149
27. DeWilde S, Carey IM, Bremmer SA, Richards N, Hilton SR, Cook DG (2003) Evolution of statin prescribing 1994-2001: a case of ageism but not sexism? Heart 89:417-421 (Pubitemid 36379415)
28. Korhonen MJ, Helin-Salmivaara A, Huupponen R (2011) Dynamics of long-term statin therapy. Eur J Clin Pharmacol 67:925-931
29. Kildemoes HW, Hendriksen C, Andersen M (2011) Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug. doi: 10.1002/pds.2039
30. Gränsbo K, Melander O, Wallentin L et al (2010) Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 55:1362-1369
31. Carey I, DeWilde S, Shah SM, Harris T, Whincup PH, Cook DG (2010) Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment? Nutr Metab Cardiovasc Dis. doi: 10.1016/j.numecd.2010.09.10
32. Glynn RJ, Koenig W, Nordestgaard BG, Shephard J, Ridker PM (2010) Rosuvastatin for primary prevention in older persons with elevated c-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 152:488-496
33. de Lorgeril M, Salen P, Abramson J et al (2010) Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. Arch Intern Med 170:1032-1036
34. Helin-Salmivaara A, Lavikainen P, Korhonen MJ et al (2008) Long-term persistence with statin therapy: A nationwide register study in Finland. Clin Ther 30:2228-2240
35. Ali RC, Melloni C, Ou F-S et al (2009) Age and persistent use of cardiovascular medication after acute coronary syndrome: Results from medication applied and sustained over time (MAINTAIN). J Am Geriatr Soc 57:1990-1996
36. Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R (2011) Statiinien käyttö yleistyy myös vanhimmissa ikäluokissa. Suom Lääkäril 66:1930-1933 [in Finnish]